DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* IPSOGEN *


 

1999 - Méditerranée
Marseille
www.ipsogen.com

 

Discovery, Diagnostics
Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia
Mission: to design, manufacture and market molecular assays with proven expertise in identifying and translating key discoveries into essential tests intented to support personalized approach to cancer treatment
Clients: Research labs, Prescribers
infos@ipsogen.com

Age: 17 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Fert (Vincent) [co-founder, born 1959, Ms. immunology, ex-Immunotech, Beckman Coulter]
Sc.Dir.-CSO: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS]
Oper.Dir.-COO: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter]
Med.Dir.-CMO: Peyro-Saint-Paul (Hélène) [M.D. (Neurology), MBA (Essec), ex-B.M.S., Actelion, Serono]
Fin.Dir.-CFO: Boissel (Pascale) [HEC, ex-Price Waterhouse Coopers, Danone, Lafarge]
SalesMktg: Danan (Corinne) [ISC, MBA (Insead, 1990), ex-Monogram Biosciences, Eli Lilly]
BusDev:
Financers (Hist.): Samenar (Caisse d'Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public
Note : trade mark logo : «Ipsogen, cancer profiler»

Turnover (M€) : 8.37 (2010), 3.33 (2008)
Total funding (M€) : 26.2
Last funding (M€) : 1.9
Focus : Cancers
Position : Trade
Company confirm : 2-May-2011

 

History
DATEMILESTONETYPETIME
2011 .07 Acquisition by Qiagen (preliminary approval to acquire 62.5% stake) ACQ- [11 years]
2011 .04 Partnering distribution agreement with Sysmex for the Japanese commercialization of certain blood cancer products MKTG [11 years]
2010 .06 Financing : 1.9 M€ reserved capital increase RFIN [10 years]
2010 .01 Licensing-in (option) on rights of TET2 abnormalities to improve the diagnosis of Blood-based Disorders, owned by a consortium of 7 public institutions led by IGR&D (IGR) LICIN [10 years]
2009 .12 Partnering research agreement with Institut Curie, on Genomic Grade, a molecular diagnostic tool for breast cancer R&D [10 years]
2009 .06 Financing : 2.5 M€ reserved capital increase RFIN [9 years]
2008 .11 Launch of MapQuant Dx, a new test to determine tumor HER2 status and guide Herceptin prescription in breast cancer (Europe) MKTG [9 years]
2008 .08 Licensing-out to Quest Diagnostics for the use of the JAK2 V617F mutation into Quest kits in USA researche centers (non-exclusive, followed by Arup, alos for uSA, in May 2009) LICOUT [8 years]
2008 .06 Listing on Alternext : 11.8 M€, i.e. 35% of shares (oversubscribed) PBO [8 years]
2007 .11 3rd round-financing : 2.0 M€, by Connecticut Innovations, and previous shareholders RFINC [8 years]
2005 .03 Set-up of US subsidiary (operations) in Connecticut State ORGC [5 years]
2005 .02 2nd round-financing : 3.5 M€, by previous shareholders RFINB [5 years]
2001 .07 1st round-financing : 4.5 M€, led by Société Générale A.M., with Matignon Technologies, Innovéris RFINA [1 year]
1999 .09 Company founded by Vincent Fert (CEO), Stéphane Debono, Fabienne Hermitte ORGF [0 year]

Actualisation / Updating: 23-Sep-2011

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende